A Single Blind Study of the Efficacy and Safety of Interleukin-1 Receptor Antagonist for the Treatment of Methacholine Induced Bronchospasm in Patients with Chronic Asthma
MetadataShow full item record
This study evaluated the effects of the Interleukin I receptor antagonist (IL 1-ra) in the treatment of asthma. Patients were selected to participate that had suffered from asthma, as defined by the American Thoracic Society, for more than two years. These patients received daily injections of the IL 1-ra for one week although they were blinded to the medication. After one week of treatment patient pulmonary function tests and methacholine challenge tests were evaluated to check for improvement. If there was improvement the patient would begin a washout period and receive placebo injections for one week. If there was no improvement the patient would receive a second week of IL1-ra injections. Following the second week of treatment patient pulmonary function and methacholine challenge tests were again evaluated, and the efficacy of the IL 1-ra determined by the change in the methacholine challenge and pulmonary function tests. 8 patients participated in the study. IL 1-ra did not prove efficacious in the treatment of their asthma, and due to the large number of adverse events associated with the IL 1-ra injections the study was discontinued prematurely.